Mediação dos receptores TLR2, NOD1, e da proteína MYD88 na modulação da mucosite intestinal induzida pelo irinotecano

• Ano de defesa: 2013
• Autor(a) principal: Wong, Deysi Viviana Tenazoa
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Camptotecina; Mucosite; Receptores Toll-Like; Proteína Adaptadora de Sinalização NOD1
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/10654

The Colorectal Cancer (CRC) is one of the most prevalent neoplastic diseases in the world and is one leading cause of death. Irinotecan is a drug used as first line treatment for CRC and its liver metastases and has markedly improved the overall survival of patients. However, irinotecan-related side-effects, which include intestinal mucositis (IM), have impacted negatively on therapeutic outcome, leading to delayed chemotherapy cycles, dose reductions and treatment interruption. IM and life-threatening diarrhea may affect up to 15-25% of patients under irinotecan-based cancer chemotherapy regimens. Aims: To study the intestinal barrier function and the mechanisms involved in the IM induced by irinotecan and its active metabolite, SN-38. Methods: Male C57BL/6 mice (WT, n=6-8) were divided into groups and injected with saline (5 mL/kg, i.p.) or irinotecan (IRI, 75 mg/kg, i.p.) for 4 days. Body weight, diarrhea and blood leukocyte count were assessed on days 5 [D5] and 7 [D7]. Following euthanasia, intestinal samples were collected for histopathology, morphometry, mieloperoxidase and imunohistochemistry assays. In addition, in vivo intestinal permeability and perfusion tests were performed. Bacteremia and bacterial translocation to mesenteric lymph node and liver were further carried out. Additionally, the participation of toll-like receptors 2 (TLR2), 4 (TLR4) and 9 (TLR9), the adaptor protein MyD88 and NOD1 receptor in the pathogenesis of IM were investigated by the use of WT mice and knockout with target gene disruptions. Furthermore, the in vivo and in vitro effects of SN-38 were studied. Data analysis was performed with ANOVA/Bonferroni’s test or Kruskal Wallis/Dunn’s test. P<0,05 was accepted. (CEPA 99/10). Results. IRI-injected WT mice presented a marked (P<0.05) weight loss, leukopenia, diarrhea, increased neutrophil infiltration in lung, jejunum, ileum associated with villi and crypt morphologic alteration and apoptotic cell death versus saline-administered mice. Besides, reduced lactulose renal excretion, gut secretion of sodium, potassium and chloride evidenced intestinal barrier dysfunction in IRI-injected WT mice versus saline-administered control mice (P<0.05). Bacterermia and bacterial translocation to mesenteric lymph node and liver were also observed in the IRI group. Biochemical identification of translocating bacteria revealed the presence of Escherichia coli (75%), Citrobacter sp. (17.2%), non-fermenting gram-negative bactéria and Pseudomona aeruginosa (18%) in blood samples of IRI-injected mice. In addition, an increased TLR4 imunoexpression was detected in that group (IRI D5: 4[3-4] and D7: 4[3-4]) when compared with saline control (1.5[1-4]). Gene deletion to TLR2 and MyD88, but not to TLR4 or TLR9, prevented weight loss, diarrhea, intestinal morphometric alterations, neutrophil infiltration in the gut and bacteremia development versus the IRI-injeted WT group (P<0.05). However, NOD1 deletion was protective only against IRI-induced diarrhea without affecting the inflammatory infiltration. Furthermore, SN-38 promoted a marked neutrophil infiltration in ileum loops (P<0.05) but did not induce intestinal secretion of liquids (P>0.05) versus saline injected mice. Besides, cultured intestinal cells (IEC-6) incubated with SN-38 presented morphological changes in comparison to DMEN-cultured cells. Conclusions: IRI induced functional alterations in the gut and also bacteremia and bacterial translocation to peripheral organs. TLR2 and MyD88 deficiency prevented IRI-related intestinal damage and the diarrhea. However, NOD1 deficiency was protective only against diarrhea development. In addition, SN-38 might be responsible for the intestinal inflammatory reaction without affecting gut secretion of liquids.